Brind.

Tempus and Natera are operating in the competitive field of ctDNA diagnostics.

1 report, 1 independent Updated Jul 15

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Tempus Natera

How it developed

Newest first. Tap a step to see who reported it.

Jul 21Tempus and Natera are subject to new financial analysis from BNP Paribas and William Blair regarding valuation and strategic fit.Sub-event
Jul 15Tempus and Natera compete in the ctDNA diagnostics market.1 source
- Insider Monkey

Keep exploring

The entities involved

Tempus
biotechnology company based in Chicago, Illinois
- Tempus is scheduled to participate in a conference in New York City on September 4, 2025.Sun 01:41
- Tempus AI, led by Eric Lefkofsky, is acquiring Paige to enhance its digital pathology datasets.Sat 00:42
Natera
company in San Carlos, United States
- Natera and Fractyl Health, biotech companies, traded on the NASDAQ stock exchange on September 1, 2026.Mon 02:47
- Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44

Coverage

Newest first; wire copies grouped

Jul 15Insider MonkeyNatera, Inc. (NTRA): A Bull Case Theory We came across a bullish thesis on Natera on Base by Base's Substack by Edward Larkin. As of 9ᵗʰ July, Natera's share was trading at $158.48. NTRA's forward P/